Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension

Sponsored by UCB Pharma

Feb 01, 2024 9:00 am

Click to download or view mobile version

#navpanes=0&scrollbar=0

Presentation

X. Baraliakos

Xenofon Baraliakos discusses the poster.

Author(s):

Atul Deodhar, Victoria Navarro-Compán, Denis Poddubnyy, Lianne S. Gensler, Sofia Ramiro, Tetsuya Tomita, Helena Marzo‑Ortega, Carmen Fleurinck, Thomas Vaux, Ute Massow, Désirée van der Heijde, Xenofon Baraliakos (narrating author)

Abstract or description:

This study aimed to report the long-term safety and efficacy of bimekizumab (BKZ) in patients with active ankylosing spondylitis (AS) up to 5 years of treatment in the phase 2b study BE AGILE and its open-label extension (OLE).

More Virtual Posters

Time to Clinical Response Poster

Time to Clinical Response to Secukinumab Across Disease Domains Among Patients With Psoriatic Arthritis: a Pooled Post Hoc Analysis of 4 Phase 3 Trials

Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-Year Final Results of a Prospective Real-World Study

AbbVie March 2025

Real-world outcomes in patients with RA remaining on first-line TNFi

AbbVie March 2025

Long-term maintenance of response of an IL-23i in PsA

Presentation

X. Baraliakos

Xenofon Baraliakos discusses the poster.

Author(s):

Atul Deodhar, Victoria Navarro-Compán, Denis Poddubnyy, Lianne S. Gensler, Sofia Ramiro, Tetsuya Tomita, Helena Marzo‑Ortega, Carmen Fleurinck, Thomas Vaux, Ute Massow, Désirée van der Heijde, Xenofon Baraliakos (narrating author)

Abstract or description:

This study aimed to report the long-term safety and efficacy of bimekizumab (BKZ) in patients with active ankylosing spondylitis (AS) up to 5 years of treatment in the phase 2b study BE AGILE and its open-label extension (OLE).

×